

The microbiome of the nasopharynx

Matthew Flynn^{1,2,*} and James Dooley¹

Abstract

The nasopharyngeal microbiome is a dynamic microbial interface of the aerodigestive tract, and a diagnostic window in the fight against respiratory infections and antimicrobial resistance. As its constituent bacteria, viruses and mycobacteria become better understood and sampling accuracy improves, diagnostics of the nasopharynx could guide more personalized care of infections of surrounding areas including the lungs, ears and sinuses. This review will summarize the current literature from a clinical perspective and highlight its growing importance in diagnostics and infectious disease management.

INTRODUCTION

As a microbiological niche, the nasopharynx (NP) demands an increased understanding of its dynamics, as the last ecological reservoir bordering the relatively microbially scarce lower respiratory tract, sinuses and middle ear [1–4]. Infections of these three sites respectively represent the leading cause of childhood and neonatal mortality worldwide [5], the second most commonly antimicrobial-overprescribed [6], and the most common reason to seek medical attention for under-5s in the USA [7]. In an era of antimicrobial resistance, translation of research from emerging molecular techniques and clinical stewardship measures will determine efficacious treatment [8, 9]. Whilst the oral flora are as logical a source of the microaspirations that seed lower airway disease as the NP, it seems to develop on a different taxonomic axis early in life [10–13]. Indeed, loss of oral/NP dissimilarity caused by, or associated with influx of oropharyngeal taxa into the NP precede respiratory tract infections (RTIs) [14]. As microbiological knowledge develops from a Kochian dichotomy of infection and health, the patient may in future be increasingly stratified within severity scales of disease or specific microbial profiles predictive of worse outcomes. The ‘Feverpain’ score stratifying patients into groups of relative risk of oropharyngeal streptococcal isolation based on symptomatology, and a classification model predicting Paediatric Intensive Care admission based on patient characteristics and isolated pathogens, are early examples of this [15, 16]. This review will describe the evolution of the healthy NP microbiome, its relevance to disease of the lower airways, sinuses and middle

ear, and propose further areas of investigation and evidence synthesis.

Colonisation over lifespan

In the first year of life the genera *Moraxella*, *Streptococcus*, *Corynebacterium*, *Staphylococcus*, *Haemophilus* and *Alloicoccus/Dolosigranulum* predominate, with likely ancestry from maternal skin, vaginal and breast milk progenitors [17, 18]. The NP rapidly develops as a distinct niche from the oral cavity with a seemingly protective increase in diversity [19]. Serial sampling of the NP in relatively healthy (>3 RTIs per year) children >1 yr with a showed early overgrowth with streptococcal spp., supplemented by *Corynebacterium* and *Dolosigranulum* with later colonization with *Moraxella* after 2–3 months. These roles were reversed in those with increased RTI frequency where *Moraxella* dominated earlier and *Corynebacterium* and *Dolosigranulum* remained less established [20]. Similarly, pre-term NPs are associated with within-group heterogeneity compared to the full term, a potential instability mimicking that seen in ensuing Rhinovirus infection, notably decreased abundance of *Corynebacterium* and *Alloicoccus* [21]. At 18 months, *Enhydrobacter* replaces streptococcal spp. when describing the six predominating operational taxonomic units (OTUs) (defined as being present in over 50% of nasopharyngeal samples). Indeed *Proteobacteria*, along with *Fusobacteria* and *Cyanobacteria*, achieve a seasonal abundance in autumn/winter that is lost by spring, which invites transient growth of *Bacillus*, *Brevibacillus*, *Lactobacillus* and *Bacteroidetes*. In this

Received 10 September 2020; Accepted 19 April 2021; Published 24 June 2021

Author affiliations: ¹School of Biomedical Sciences, Ulster University, Coleraine BT52 1SA, UK; ²Otolaryngology Department, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.

*Correspondence: Matthew Flynn, flynn-m5@ulster.ac.uk

Keywords: nasopharyngeal; microbiome; respiratory virus; bacterial infection.

Abbreviations: AN, anterior nares; NP, nasopharynx; OM, otitis media; OTU, operational taxonomic units; RSS, acute rhinosinusitis; RTI's, respiratory tract infections; TLR, toll-like receptor; WGS, whole genome sequencing; WHO, World Health Organisation.

001368 © 2021 The Authors



This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author's institution.

study, the overall microbial diversity of the nasopharynx did not significantly fluctuate between autumn, winter and spring [22]. Over childhood and into adulthood there develops a richness in NP taxa, accompanied by increased evenness [23] and diversity in neighbouring oropharyngeal flora, relative to adults and elderly presenting to the emergency department with pneumonia [24]. Within adults aged 50–80, there is a greater absolute number of pathogens extracted by swabs in men compared to women [25]. The topographical dissimilarity between the anterior nares and oropharynx seen in the middle aged is lost within the elderly population; such transitions in microbiome may precipitate or avail of increased susceptibility to disease in this population [26]. This mimics the loss of variance between the oral and nasopharyngeal diversity associated with predisposition to disease early in life [27]. However larger more longitudinal studies within the adult population are required to describe the vectors therein.

Environmental/aetiological factors influencing NP microbiome composition

The evolution of the healthy microbiome cannot be reduced to a gradual collection of key OTUs upon the epithelial seabed. Many other aetiological and iatrogenic factors affect its development. Breastfeeding showed a significant change in the 6 week microbiome compared with formula feeding, notably with increased presence and abundance of classically commensal *Dolosigranulum* and *Corynebacterium* [28]. Significant decrease in abundance of these two potentially keystone species is noticed in infants who had antibiotic use in the preceding 4 weeks before sampling [29]. Short-term corticosteroid inhalation was not found to significantly alter the nasopharyngeal microbiome, but longer-term studies are needed [30]. Smoking appears to have a positive impact on the raw incidence of known pathogenic genera, and suppressing key ‘interfering’ species, but many of these studies have been underpowered [31, 32]. Lower socioeconomic indicators correlate with increased prevalence of *M. catarrhalis*, *S. aureus* and antibiotic-resistant *S. pneumoniae*, and epidemiological factors such as older siblings, daycare attendance and rural occupancy exerted a positive pressure toward pathogen carriage [33, 34]. These studies were conducted with traditional culture, not quantitative and sensitive molecular techniques however, therefore potential for false negatives is high. Pig farming has a positive and unsurprising effect on nasopharyngeal diversity indicating that the external environment has a key role in determining the final NP microbiome composition [35]. In line with similar findings in the gingivae and dental plaques, bacterial biofilms have been established as a mode of survival on the adenoidal surface [36–38]. As a sustaining and protective extracellular resin, biofilm is emerging as a necessary *in vivo* concept with relevance to therapy and microbial synergy in understanding the microbiome in health [39]. Whether or not biofilms are a driver of respiratory disease is yet to be established [40]. This rise in incidence of pathobionts is also noticed with lower lean body mass to fat ratios in men and higher waist-to-hip ratios in females, both considered markers of fertility and immune

competence [41]. Immunomodulatory effects are noticed in raised serum Vitamin D levels, which reduce self-reported symptoms of the upper RTI: ears, sinuses, malaise and use of antibiotics in the immunosuppressed, and Vitamin D also augments dendrocyte maturation and matriculation against pneumococcal peptidoglycan *in vitro* [42, 43]. The asthmatic core microbiome identified in a study with mean age 11 years mimicked the previously described core microbiome at 18 months, but without *Enhydrobacter* and with *Moraxella*, *Haemophilus* and *Streptococcus* being observed in 95% of samples, the same trio previously noticed in Rhinovirus susceptible infants [44, 45]. There may be further unknown pharmacological, meteorological or behavioral pressures as yet unstudied.

Pathogens, pathobionts and commensals: changing roles for the NP microbiome

The diverse microbial landscape is further involved by the relative pathogenicity of organisms, with microbes traversing the commensal-pathogen continuum depending on circumstance and coinfection. Pneumococcus for instance, commonly considered the main causative agent of pneumonia, may be considered a member of the healthy nasopharynx [46], and conversely species considered normal commensals may be implicated in severe disease of the immunocompromised [47]. The introduction of the pneumococcal vaccine has reduced disease burden, but has led to serotype replacement of *S. pneumoniae*, and immediate epidemiological shifts in carriage of non-typable *Haemophilus influenzae* [48, 49]. Similarly *Moraxella* spp., long considered a benign human symbiont, has been implicated in a consistent percentage of middle ear and sinus infections, and are an important cause of exacerbations of chronic obstructive pulmonary disease [50]. Colonization rates, determined by culture, of *S. pneumoniae*, *S. aureus* and *M. catarrhalis* were significantly higher in patients with variant types of mannose-binding lectin, Toll-like receptor 2 (TLR2) and TLR4, respectively, receptors upregulating the innate immune system derived from polymorphic alleles, suggesting a genetic basis for variable colonization [51]. The underlying bacteria–bacteria and virus–bacteria and immune–bacterial interactions are complex, and the exact link between competition, overgrowth and disease manifestation requires considerable future study [52, 53].

The virome and mycobacteriome in health

The NP virome is a common cause of upper respiratory illness. Metagenomic analysis of NP swabs yielded a mean 86 viral sequences per sample in children under 3 with unexplained fever, compared with 56 from health controls, as well as greater richness and diversity [54]. This greater yield was a contradiction to previous purely PCR-based studies with little or no viral load detected in normal controls, controls which though significantly predict health, suggest a benign carriage akin to the commensal bacteriome [55, 56]. This high sensitivity of viral presence in under 3s via next-generation sequencing was replicated in a second case-controlled study, where 71.2

% 'healthy' NPs contained viral nucleic acid compared with 94.4% of children with recurrent otitis media, with Polyomavirus, Bocavirus and Rhinovirus prevailing in health, the latter with incidence as high as 42.4% [57]. The Anelloviridae family however has been identified as the most prevalent in febrile children on metagenomic analysis [58]. Anthropologically, the presence of various Rhinovirus strains occur between aboriginal and non-aboriginal children at different rates, and are associated with *Moraxella* and *H. influenzae* within both populations, pathogens deemed responsible for otitis media [59, 60]. *Haemophilus* is further overrepresented in infants hospitalized with Respiratory Syncytial Virus (RSV) and drives response of mucosal cytokine CXCL8, while clearance of RSV is delayed in infants with a *Haemophilus* dominated NP microbiome [61, 62]. More recently, comparison of COVID-19 specimen collections under strict conditions favoured the NP as more likely to yield the virus than the oropharynx [63]. NP dysbiosis has also been associated with disease severity in *Mycoplasma pneumoniae* pneumonia compared with healthy controls [64]. Fungal disease is not normally implicated in the NP being unique to the paranasal sinuses [65].

Lung, sinus and gastrointestinal relationships to the NP microbiome

The microbiome of the lung has been described as ecologically similar to the NP. The relatively abundant phylae *Bacteroides*, *Firmicutes* and *Proteobacteria*, however, have been a subject of doubt, whether selectively repatriated from the upper respiratory tract, or selectively contaminated whilst sampling the oropharynx [66]. Sterile dissection of healthy smokers' lungs have confirmed this microbiome, distinct from the oral cavity or nasopharynx, and more robust models of sterile sampling and controls for lavage contamination and oropharyngeal sampling confirm specifically lung-enriched organisms [67, 68]. As well as a source of emissary pathogens to the lungs, the NP microbiome may offer a diagnostic window to the rest of the respiratory tract. Furthermore, prevalence of keystone species at this level may gate downstream transmission of pathogens by colonization resistance [69]. Asthma control tests, an indication of how well asthma has been controlled over the preceding 4 weeks, was significantly lower in subjects with no viruses detected on NP swabbing than those with detected viruses [70]. NP swabs clear of viruses demonstrated lower NP microbiota compositions vary not only with RTIs but gastrointestinal infections also, inferring synergy of the wider metabiome [71]. Acute rhinosinusitis (RSS) is marked by symptoms of nasal congestion and nasal discharge, or facial pain or anosmia [72]. Prior history of RSS was associated with a significant depletion of NP taxa from over 100 genera, with only the species *Moraxella nonliquefaciens* demonstrating an increase in relative abundance [73]. Longitudinal studies through acute disease are required to describe dynamics more fully, but such statistically outlying OTUs, if detected on a consistent basis, may serve as biomarkers to predict or confirm disease. The NP acting as a reservoir for sinus infection model has been supported

by a conventional culture study linking successfully detected pathogens at the osteomeatal complex in the mid-nasal cavity to a >90% coincidence in the NP [74]. More recent gene sequencing of microbiota from functional endoscopic sinus surgery patients found a microbiome similar to the anterior nares (AN), which became transiently similar to the NP at the time of operation, and then regressed to its original niche equilibrium after 6 weeks [75]. Dissimilarity between the almost isolated sphenoid sinus and the rest of the nose, manifests as increased detection rates of resistant commensals and anaerobes, however this study was underpowered and used culture techniques [76]. Multidisciplinary collaboration between clinicians and scientists along both respiratory and age continua will be required to further characterize their dynamics and provide clinical application.

Otitis media

The otitis media (OM) culprit pathobiont triad in the conventional culture era were *Haemophilus influenzae*, *Moraxella catarrhalis* and *Streptococcus pneumoniae*, joined by *Alloio-coccus otiditis* with PCR-based diagnostics, a pathogen so ubiquitous in the middle ear of previously antibiotic treated children as to raise suspicion of a facultative or saprotrophic nature [77–79]. *Alloio-coccus*, however, was found to be absent in the NP and predominating in cultures of middle ear fluid from perforated eardrums, suggesting its external ear origin [80–82]. The NP of children with OM, in whom it is relatively prevalent, is implicated with the above three classically cultured pathogens [83]. Quantitative-PCR detected the prevalence of *Haemophilus* in OM approaching the 90% NP detection rate of the same pathogen, a correlation not shared by *Moraxella* and *Streptococcus* spp. [84]. Next-generation sequencing of the NP in recurrent acute OM patients showed increased abundance of *Corynebacterium* and *Dolosigranulum* in healthy controls, with a lesser role played by *Moraxella*. *Dolosigranulum pigrum* is closely related to *Alloio-coccus*, and *Corynebacterium* is from the same family as the otopathogen *Turicella*, suggesting possible colonization resistance for at least these genera [85]. These two, however, are very successfully inhibited by β -lactam antibiotics, therefore measures to employ more judicious use of these agents would be welcomed [86–88]. A more amenable relationship between bacteria–virus co-offenders *S. pneumoniae* and Rhinovirus, and *Moraxella* and Adenovirus, is evident in their statistically correlated abundance in recurrent acute OM in one cross-sectional study. With a 25% co-occurrence of most abundant viruses Rhinovirus and Bocavirus within its healthy controls, this may be a baseline virome not displaying obligate pathogenicity [89]. This opportunism spotlights a realm of known unknowns within aetiological factors capable of tipping this dormant microbiome into disease.

NP profiling and health

NP microbiota in children under 1 year with bronchiolitis dominated by *Haemophilus* and with low levels of CCL5, a β -chemokine, has linear positive correlation with hospital stay when a *Moraxella*-dominated profile is used as a control, and

that this trend was maintained when an AN swab was utilized. The AN is a not entirely comparable microbiological niche, where staphylococcal species represent 40 % total abundance compared to >5% in the NP [90–92]. Further profiling of the AN in a similar cohort showed the lowest proportion of patients developing severe bronchiolitis in the *Moraxella*-dominant group (14%) compared with *Staphylococcus*-dominated (47%). It is intriguing to speculate whether a similar trend could be found further back in the nasal cavity [93]? Bronchiolitis treatment escalation to mechanical ventilation was predicted specifically and sensitively by a select panel of 25 metabolites, which in turn mirrored relative abundance of *S. pneumoniae*, thus promoting the metabolome as a bacterial marker [94]. A multivariate analysis of associations of the NP microbiome within patients showed positive association with *S. pneumoniae* and *H. influenzae* and *M. catarrhalis*, siblings, daycare use, rhinoviruses and enteroviruses. There was a corresponding negative association with *S. aureus* carriage, recent antimicrobials, and the 7-valent pneumococcal vaccine [95]. A similar profiling of NP microbiota and patient characteristics established a ‘high’ degree of accuracy in predicting lower RTI and length of hospital stay from a 29-point score derived of the most indicative bacteria and viruses and patient factors. Thus antimicrobials are strongly indicated to prevent severe pneumonia, but with an underlying need for a stratified approach. It found relative scarcity of *Dolosigranulum* and *Corynebacterium* spp. and to a slightly lesser extent *Moraxella* spp. in those escalated to intensive care compared with controls [96]. Characterization of the NP microbiomes’ ability to prevent or accelerate viral respiratory infection is frustrated by the heterogeneity of study methods, lack of data from adult populations and poor taxonomic resolution [97]. Furthermore, the immune response against viruses is in turn modulated by gut microbiota, susceptible to the same deleterious effects from antimicrobials [98]. Nevertheless, in the light of the coronavirus pandemic of 2020, a theoretical underpinning for protective NP profiles could not be more welcome.

The nasopharyngeal microbiome and antimicrobial resistance

Pressure on the NP microbiome by antibiotics could yield less protective profiles. Alpha diversity decreases linearly with antibiotic doses, whilst significantly increased relative abundance of *Haemophilus* is found in children aged 1–6 who had received antibiotics in the preceding 3 months compared to those who had not [99]. Thus, even before resistant pathogens are detected, disease susceptible states can persist following antibiotic use. *S. pneumoniae* resistant to Amoxicillin, Erythromycin and Co-Trimoxazole persist at stable rates throughout the first year of life within the South African population despite pneumococcal vaccination at 6 weeks, and despite only 4% of HIV-exposed infants receiving the recommended Co-trimoxazole prophylaxis [100, 101]. Whole-genome sequencing (WGS) is more sensitive for detection of potential pathogens in patients with recent antimicrobial use compared to conventional

culture [102]. The advent of WGS has shown great promise for decision-making around patient isolation, with the use of rapid WGS to classify skin and gut commensals in one hospital leading to a net saving of €200,000 in blocked beds over 6 months despite high sequencing costs [103]. Such de-escalation of care would be well adapted to the high antimicrobial use seen in the upper respiratory tract.

Sampling the NP

Accurate sampling of the NP tract remains a challenge to establishing a baseline NP microbiome. Despite the technique of nasopharyngeal swabbing and washes being standardized by the World Health Organization (WHO), considerable heterogeneity had been noted within clinical practice during the COVID-19 pandemic [104–107]. The nasopharynx is defined as a subcomponent of the upper throat or posterior nasal cavity. However during a recent systematic review of the scientific literature using risk-of-bias assessments and quality checklists, the anterior nares and posterior oropharyngeal wall have been found to be included within the term ‘nasopharynx’ [108, 109]. Accuracy is important: alpha diversity indices for brushings of the inferior turbinate was increased vs. washings of the whole nasal cavity; whether this was due to a richer sampled environment or removal of pathogens with a greater range of mucosal adhesion is difficult to assess [110]. Biogeography of the sphenoidal recess and middle meatus displayed similar ecosystems likely related to their ciliated pseudostratified columnar epithelium, and dissimilar to the nonkeratinized, squamous epithelial inhabitants of the AN [111, 112]. Such studies rely on specialist equipment and expertise to accurately sample different sites. In some studies, nasal washings have yielded a higher colonization rate than swabbing of the posterior NP, but with implications of discomfort and suitability for an older paediatric/adolescent population [113–115]. Interestingly, once at the nasopharynx, completing the mandatory rotations did not have a major effect upon discomfiture [116]. Contamination of sampling by sites encountered *en passant* has to be a key consideration when moving beyond single pathogen carriage to quantifying microbial communities. Otolaryngological expertise has been relied on to specifically sample the nasopharynx in isolation [117, 118]. Innovation for this problem may include a ‘punch mechanism’ swab or a retractable guard for the swab head to sample the back of the nasal cavity only. When removed, the samples may themselves display further interactions: broth enrichment has been shown to favour overgrowth of phyla that would be disadvantaged *in vivo* at the expense of pathogens, and storage conditions affect microbial profiles as detected by 16S rRNA gene sequencing [119, 120]. The limitations of conventional culture persist from the laboratory to the clinic, with pathogen detection on sinus culture being unable to identify patients who would develop RSS-consistent radiological changes [121]. For pathogens enmeshed within biofilm, fluorescent *in situ* hybridization (FISH) had around twice the sensitivity of culture, invoking

deeper sampling techniques for these landscapes [122]. Similar challenges exist with viruses: amplification of the specific fragment of the genome of common respiratory viruses via PCR has a sensitivity as low as 53 % with enzyme linked immunosorbent assay, and 71% by PCR [123, 124].

Conclusion and future steps

The NP is an emerging arena in the fight against pneumonia and upper RTIs, and a reservoir evolving specific resistance patterns [125]. Encouraging developments have included the increase in diversity and stability of the NP microbiome since introduction of 7- and 13-valent pneumococcal vaccines, preceding a reduction in the incidence of OM [126]. Ingestion of probiotic yoghurt shows a significant decrease in the prevalence of Gram-positive pathobionts in humans, whilst probiotic application of *Corynebacterium* strains has been shown to replace *S. aureus* in humans and reduce viral load, lung changes and weight loss during RSV infection in mice [127–129]. Moving from marksmanship of culprit pathogens to shotgun sequencing of a patient's entire microbiota at time of acute illness will guide increasingly accurate and judicious treatment of NP-derived infections. WGS is already being used to trace epidemiological links within outbreaks such as COVID-19 [130, 131]. For more common infections, 'syndromic panels' to detect carriage of a wide array of microbiota direct from samples have been available for the last decade [132]. Initial data on non-rapid WGS, defining infection as patients with exponentially prevalent overgrowth of key pathogens, suggests it can yield greater sensitivity, if not specificity, than conventional culture. Marriage of these technologies could inform front-of-house clinical decisions for more common infections in future. The generation of patient-specific microbial profiles may be able to distinguish health from disease, resistance patterns and specific dysbioses through emerging point-of-care whole-genome sequencing and clinical prediction tools [133, 134]. Such profiles available to clinicians may aid in decision making around ventilation, detection of disease in other body systems, and even transplantation of new microbiomes [135–137].

Funding information

This work received no specific grant from any funding agency.

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

- Dickson RP, Erb-Downward JR, Freeman CM, McCloskey L, Beck JM, et al. Spatial variation in the healthy human lung microbiome and the adapted Island model of lung biogeography. *Ann Am Thorac Soc* 2015;12:821–830.
- Boeck D, Wittouck S, Martens K, Claes J, Jorissen M, et al. Anterior nares diversity and pathobionts represent sinus microbiome in chronic rhinosinusitis. *mSphere* 2019;4.
- Rawlings B, Higgins T, Han J. Bacterial pathogens in the nasopharynx, nasal cavity, and osteomeatal complex during wellness and viral infection. *Am J Rhinol Allergy* 2013;27:39–42.
- Lappan R, Imbrogno K, Sikazwe C, Anderson D, Mok D, et al. A microbiome case-control study of recurrent acute otitis media identified potentially protective bacterial genera. *BMC Microbiol* 2018;18.
- Ending Preventable Child Deaths from Pneumonia and Diarrhoea by 2025. *The integrated Global Action Plan for Pneumonia and Diarrhoea (GAPPD)*. WHO Press, 2013
- Dekker A, Verheij T, van der Velden A. Inappropriate antibiotic prescription for respiratory tract indications: most prominent in adult patients. *Fam Pract* 2015;32:401–407.
- Grijalva CG, Nuorti JP, Griffin MR. Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings. *JAMA* 2009;302:758–766.
- Köser CU, Ellington MJ, Peacock SJ. Whole-genome sequencing to control antimicrobial resistance. *Trend Genet* 2014;30:401–407.
- Flynn M, Hooper G. Antimicrobial stewardship through FeverPAIN score: Successes and challenges in secondary care. *Clin Infect Practice* 2020;7-8:
- Huxley E, Viroslav J, Gray W, Pierce A. Pharyngeal aspiration in normal adults and patients with depressed consciousness. *Survey Anesthesiol* 1979;23:203.
- Charlson ES, Bittinger K, Haas AR, Fitzgerald AS, Frank J, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. *Am J Respir Crit Care Med* 2011;184:957–963.
- Wang H, Dai W, Feng X, Zhou Q, Wang H, et al. Microbiota composition in upper respiratory tracts of healthy children in Shenzhen, China, differed with respiratory sites and ages. *Biomed Res Int* 2018;2018:6515670.
- Stearns JC, Davidson CJ, McKeon S, Whelan FJ, Fontes ME, et al. Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age. *ISME J* 2015;9:1246–1259.
- Man WH, Clerc M, de Steenhuijsen Piters WAA, van Houten MA, Chu MLJN, et al. Loss of microbial topography between oral and nasopharyngeal microbiota and development of respiratory infections early in life. *Am J Respir Crit Care Med* 2019;200:760–770.
- Man W, van Houten M, Mérelle M, Vlieger A, Chu M, et al. Bacterial and viral respiratory tract microbiota and host characteristics in children with lower respiratory tract infections: a matched case-control study. *Lancet Respir Med* 2019;7:417–426.
- Little P, Hobbs FD, Moore M, Mant D, Williamson I, et al. Clinical score and rapid antigen detection test to guide antibiotic use for sore throats: randomised controlled trial of PRISM (primary care streptococcal management). *BMJ* 2013;10:f5806.
- Teo SM, Mok D, Pham K, Kusel M, Serralha M, et al. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 2015;17:704–715.
- de Steenhuijsen Piters WA, Sanders EA, Bogaert D. The role of the local microbial ecosystem in respiratory health and disease. *Phil Trans R Soc Lond B Biol Sci* 2015;370:20140294.
- Man WH, Clerc M, de Steenhuijsen Piters WAA, van Houten MA, Chu MLJN, et al. Loss of microbial topography between oral and nasopharyngeal microbiota and development of respiratory infections early in life. *Am J Respir Crit Care Med* 2019;200:760–770.
- Bosch A, Piters W, van Houten M, Chu M, Biesbroek G, et al. Maturation of the Infant Respiratory Microbiota, Environmental Drivers, and Health Consequences. A Prospective Cohort Study. *Am J Respir Crit Care Med* 2017;196:1582–1590.
- Perez GF, Pérez-Losada M, Isaza N, Rose MC, Colberg-Poley AM, et al. Nasopharyngeal microbiome in premature infants and stability during rhinovirus infection. *J Invest Med* 2017;65:984–990.
- Bogaert D, Keijsers B, Huse S, Rossen J, Veenhoven R, et al. Variability and diversity of nasopharyngeal microbiota in children: a metagenomic analysis. *PLoS One* 2011;6:e17035.
- Stearns JC, Davidson CJ, McKeon S, Whelan FJ, Fontes ME, et al. Culture and molecular-based profiles show shifts in bacterial communities of the upper respiratory tract that occur with age. *ISME J* 2015;9:1246–1259.

24. de Steenhuijsen Piters WAA, Huijskens EGW, Wyllie AL, Biesbroek G, van den Bergh MR, *et al.* Dysbiosis of upper respiratory tract microbiota in elderly pneumonia patients. *ISME J* 2016;10:97–108.
25. Liu C, Price L, Hungate B, Abraham A, Larsen L, *et al.* *Staphylococcus aureus* and the ecology of the nasal microbiome. *Sci Advance* 2015;1:e1400216.
26. Whelan F, Verschoor C, Stearns J, Rossi L, Luinstra K. The loss of topography in the microbial communities of the upper respiratory tract in the elderly. *Annal Am Thoracic Soc* 2014;11:513–521.
27. Man W, Clerc M, de Steenhuijsen Piters W, van Houten M, Chu M, *et al.* Loss of microbial topography between oral and nasopharyngeal microbiota and development of respiratory infections early in life. *Am J Respir Crit Care Med* 2019;200:760–770.
28. Biesbroek G, Bosch A, Wang X, Keijser B, Veenhoven R, *et al.* The impact of breastfeeding on nasopharyngeal microbial communities in infants. *Am J Respir Crit Care Med* 2014;140:612135546007.
29. Teo SM, Mok D, Pham K, Kusel M, Serralha M, *et al.* The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 2015;17:704–715.
30. Aksoy F, Demirhan H, Bayraktar G, Yıldırım Y, Özturan O, *et al.* Effect of nasal mometasone furoate on the nasal and nasopharyngeal flora. *Auris Nasus Larynx* 2012;39:180–185.
31. Brook I, Gober A. Recovery of potential pathogens in the nasopharynx of healthy and otitis media-prone children and their smoking and nonsmoking parents. *Ann Otol, Rhinol Laryngol* 2008;117:727–730.
32. Brook I, Gober AE. Effect of smoking cessation on the microbial flora. *Arch Otolaryngol Head Neck Surg* 2007;133:135–138.
33. Jourdain S, Smeesters P, Denis O, Dramaix M, Sputael V, *et al.* Differences in nasopharyngeal bacterial carriage in preschool children from different socio-economic origins. *Clin Microbiol Infect* 2011;17:907–914.
34. Principi N, Marchisio P, Schito G, Mannelli S. Risk factors for carriage of respiratory pathogens in the nasopharynx of healthy children. *Ped Infect Dis J* 1999;18:517–523.
35. Kraemer JG, Ramette A, Aebi S, Oppliger A, Hilty M. Influence of pig farming on the human nasal microbiota: Key role of airborne microbial communities. *Appl Environ Microbiol* 2018;84.
36. Berger D, Rakhmimova A, Pollack A, Loewy Z. Oral biofilms: development, control, and analysis. *High Throughput* 2018;7:24.
37. Winther B, Gross BC, Hendley JO, Early SV. Location of bacterial biofilm in the mucus overlying the adenoid by light microscopy. *Arch Otolaryngol Head Neck Surg* 2009;135:1239–1245.
38. Coticchia J, Zuliani G, Coleman C, Carron M, Gurrola J II, *et al.* Biofilm surface area in the pediatric nasopharynx. *Arch Otolaryngol Head Neck Surg* 2007;133:110.
39. Flemming H, Wingender J, Szewzyk U, Steinberg P, Rice S, *et al.* Biofilms: an emergent form of bacterial life. *Nat Rev Microbiol* 2016;14:563–575.
40. Subtil J, Bajanka-Lavado M, Rodrigues J, Duarte A, Reis L, *et al.* Cross-sectional study of adenoidal biofilms in a paediatric population and its clinical implications. *Otolaryngol Polska* 2018;72:1–5.
41. Pawlowski B, Nowak J, Borkowska B, Drulis-Kawa Z. Human body morphology, prevalence of nasopharyngeal potential bacterial pathogens, and immunocompetence handicap principal. *Am J Human Biol* 2014;26:305–310.
42. Bergman P, Norlin A, Hansen S. Vitamin D3 supplementation in patients with frequent respiratory tract infections: a randomised and double-blind intervention study. *BMJ Open* 2012;2:e001663.
43. Olliver M, Spelmink L, Hiew J, Meyer-Hoffert U, Henriques-Normark B, *et al.* Immunomodulatory effects of vitamin D on innate and adaptive immune responses to *Streptococcus pneumoniae*. *J Infect Dis* 2013;208:1474–1481.
44. Pérez-Losada M, Alamri L, Crandall K, Freishtat R. Nasopharyngeal microbiome diversity changes over time in children with asthma. *PLOS ONE* 2017;12:e0170543.
45. See xvi, Grindle K, Johnston SL, Gern JE, Sly PD. The infant nasopharyngeal microbiome impacts severity of lower respiratory infection and risk of asthma development. *Cell Host Microbe* 2015;17:704–715.
46. Donkor ES. Understanding the pneumococcus: transmission and evolution. *Front Cell Infect Microbiol* 2013;3:7.
47. Mechergui A, Achour W, Baaboura R, Ouertani H, Lakhal A, *et al.* Case report of bacteremia due to *Neisseria mucosa*. *APMIS* 2013;122:359–361.
48. Cleary D, Devine V, Morris D, Osman K, Gladstone R, *et al.* Pneumococcal vaccine impacts on the population genomics of non-typeable *Haemophilus influenzae*. *Microb Genomics* 2018;4.
49. Gladstone R, Devine V, Jones J, Cleary D, Jefferies J, *et al.* Pre-vaccine serotype composition within a lineage signposts its serotype replacement – a carriage study over 7 years following pneumococcal conjugate vaccine use in the UK. *Microb Genomics* 2017;3.
50. Murphy T, Parameswaran G. *Moraxella catarrhalis*, a human respiratory tract pathogen. *Clin Infect Dis* 2009;49:124–131.
51. Vuononvirta J, Toivonen L, Gröndahl-Yli-Hannuksela K, Barkoff A, Lindholm L, *et al.* Nasopharyngeal bacterial colonization and gene polymorphisms of mannose-binding lectin and toll-like receptors 2 and 4 in infants. *PLOS ONE* 2011;6:e26198.
52. Reiss-Mandel A, Regev-Yochay G. *Staphylococcus aureus* and *Streptococcus pneumoniae* interaction and response to pneumococcal vaccination: Myth or reality? *Hum Vaccin Immunother* 2016;12:351–357.
53. Bosch AA, Biesbroek G, Trzcinski K, Sanders EA, Bogaert D. Viral and bacterial interactions in the upper respiratory tract. *PLoS Pathog* 2013;9:e1003057.
54. Wylie K, Mihindukulasuriya K, Sodergren E, Weinstock G, Storch G. Sequence analysis of the human virome in Febrile and Afebrile Children. *PLOS ONE* 2012;7:e27735.
55. Cai X, Wang Q, Lin G, Cai Z, Lin C, *et al.* Respiratory virus infections among children in South China. *J Med Virol* 2014;86:1249–1255.
56. Hause A, Avadhanula V, Maccato M, Pinell P, Bond N, *et al.* A cross-sectional surveillance study of Acute Respiratory Illness (ARI) in pregnant women. *Open Forum Infect Dis* 2017;4:S573.
57. Wylie KM, Mihindukulasuriya KA, Sodergren E, Weinstock GM, Storch GA. Sequence analysis of the human Virome in febrile and afebrile children. *PLOS ONE* 2012;7:e27735.
58. Wang Y, Zhu N, Li Y, Lu R, Wang H, *et al.* Metagenomic analysis of viral genetic diversity in respiratory samples from children with severe acute respiratory infection in China. *Clin Microbiol Infect* 2016;22:458.
59. Annamalai AA, Khoo SK, Jacoby P, Bizzintino J, Zhang G, *et al.* Prevalence of and risk factors for human rhinovirus infection in healthy aboriginal and non-aboriginal Western Australian children. *Ped Infect Dis J* 2012;67:3–679.
60. Moore H, Jacoby P, Taylor A, Harnett G, Bowman J. The interaction between respiratory viruses and pathogenic bacteria in the upper respiratory tract of asymptomatic aboriginal and non-aboriginal children. *Ped Infect Dis J* 2010;29:540–545.
61. Ederveen THA, Ferwerda G, Ahout IM, Vissers M, de Groot R, *et al.* *Haemophilus* is overrepresented in the nasopharynx of infants hospitalized with RSV infection and associated with increased viral load and enhanced mucosal CXCL8 responses. *Microbiome* 2018;6:10.
62. Mansbach JM, Hasegawa K, Piedra PA, Avadhanula V, Petrosino JF, *et al.* *Haemophilus*-dominant nasopharyngeal microbiota is associated with delayed clearance of respiratory syncytial virus in infants hospitalized with bronchiolitis. *J Infect Dis* 2019;219:1804–1808.
63. Wang X, Tan L, Wang X, Liu W, Lu Y, *et al.* Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously. *Int J Infect Dis* 2020;94:107–109.

64. Dai W, Wang H, Zhou Q, Feng X, Lu Z, *et al.* The concordance between upper and lower respiratory microbiota in children with *Mycoplasma pneumoniae* pneumonia. *Emerg Microb Infect* 2018;7:92.
65. Lu Y, Wang S, Liou M, Shen T, Lu Y, *et al.* Microbiota dysbiosis in fungal rhinosinusitis. *J Clin Med* 2019;8:11.
66. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. *Expert Rev Respir Med* 2013;7:245–257.
67. Erb-Downward JR, Thompson DL, Han MK, Freeman CM, McCloskey L, *et al.* Analysis of the lung microbiome in the “healthy” smoker and in COPD. *PLoS One* 2011;6:e16384.
68. Charlson ES, Bittinger K, Chen J, Diamond JM, Li H, *et al.* Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. *PLoS One* 2012;7:e42786.
69. Man W, de Steenhuijsen Piters W, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. *Nat Rev Microbiol* 2017;15:259–270.
70. Dinwiddie D, Schwalm K, Hardin O, Stoner A, Denson J, *et al.* The nasopharyngeal microbiome is perturbed during respiratory viral infections and asthmatic exacerbations. Sequencing, finishing, and analysis in the future meeting [Internet]. 2017. <http://programme.exordo.com/sfaf2017/delegates/presentation/96/>
71. Verhagen LM, Rivera-Olivero IA, Clerc M, Chu MLJN, van Engelsdorp Gastelaars J, *et al.* Nasopharyngeal microbiota profiles in rural venezuelan children are associated with respiratory and gastrointestinal infections. *Clin Infect Dis* 2021;72:212–221.
72. Fokkens W, Lund V, Mullol J, Bachert C, Alobid I, *et al.* European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *Rhinol J* 2012;50:1–12.
73. Santee CA, Nagalingam NA, Faruqi AA, DeMuri GP, Gern JE, *et al.* Nasopharyngeal microbiota composition of children is related to the frequency of upper respiratory infection and acute sinusitis. *Microbiome* 2016;4:34.
74. Rawlings BA, Higgins TS, Han JK. Bacterial pathogens in the nasopharynx, nasal cavity, and osteomeatal complex during wellness and viral infection. *Am J Rhinol Allergy* 2013;27:39–42.
75. Hauser LJ, Ir D, Kingdom TT. Investigation of bacterial repopulation after sinus surgery and perioperative antibiotics. *Int Forum Allergy Rhinol* 2016;6:34–40.
76. Shibao S, Toda M, Tomita T, Ogawa K, Yoshida K. Analysis of the bacterial flora in the nasal cavity and the sphenoid sinus mucosa in patients operated on with an endoscopic endonasal transsphenoidal approach. *Neurol Med-Chir* 2014;54:1009–1013.
77. Bluestone C, Stephenson J, Martin L. Ten-year review of otitis media pathogens. *Ped Infect Dis J* 1992;11:S7–11.
78. Hendolin P, Markkanen A, Ylikoski J, Wahlfors J. Use of multiplex PCR for simultaneous detection of four bacterial species in middle ear effusions. *J Clin Microbiol* 1997;35:2854–2858.
79. Harimaya A, Takada R, Hendolin P, Fujii N, Ylikoski J, *et al.* High incidence of *Alloiooccus otitidis* in children with otitis media, despite treatment with antibiotics. *J Clin Microbiol* 2006;44:946–949.
80. de Barre T, Hollants J, Waetens A, Huyghe J, Cuvelier C, *et al.* Otitis media microbes: culture, PCR, and confocal laser scanning microscopy. *B-ENT* 1990;5:65–72.
81. De Baere T, Vanechoutte M, Deschaght P, Huyghe J, Dhooge I. The prevalence of middle ear pathogens in the outer ear canal and the nasopharyngeal cavity of healthy young adults. *Clin Microbiol Infect* 2010;16:1031–1035.
82. Stroman D, Roland P, Dohar J, Burt W. Microbiology of normal external auditory canal. *Laryngoscope* 2001;111:2054–2059.
83. Coleman A, Wood A, Bialasiewicz S, Ware R, Marsh R, *et al.* The unsolved problem of otitis media in indigenous populations: a systematic review of upper respiratory and middle ear microbiology in indigenous children with otitis media. *Microbiome* 2018;6.
84. Smith-Vaughan HC, Binks MJ, Marsh RL, Kaestli M, Ward L, *et al.* Dominance of *Haemophilus influenzae* in ear discharge from Indigenous Australian children with acute otitis media with tympanic membrane perforation. *BMC Ear Nose Throat Disord* 2013;13:12.
85. Lappan R, Imbrogno K, Sikazwe C, Anderson D, Mok D, *et al.* A microbiome case-control study of recurrent acute otitis media identified potentially protective bacterial genera. *BMC Microbiol* 2018;18:13.
86. Martínez-Martínez L, Pascual A, Bernard K, Suárez AI. Antimicrobial susceptibility pattern of *Corynebacterium striatum*. *Antimicrob Agent Chemother* 1996;40:2671–2672.
87. Laclaire L, Facklam R. Antimicrobial susceptibility and clinical sources of *Dolosigranulum pigrum* cultures. *Antimicrob Agent Chemother* 2000;44:2001–2003.
88. National Institute for Clinical Excellence. Otitis media (acute): antimicrobial prescribing. *Public Health England* 2018.
89. Wiertsema SP, Chidlow GR, Kirkham LAS, Corscadden KJ, Mowe EN, *et al.* High detection rates of nucleic acids of a wide range of respiratory viruses in the nasopharynx and the middle ear of children with a history of recurrent acute otitis media. *J Med Virol* 2011;83:2008–2017.
90. Hasegawa K, Mansbach JM, Ajami NJ, Espinola JA, Henke DM, *et al.* Association of nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalised for bronchiolitis. *Eur Respir J* 2016;48:1329–1339.
91. Hasegawa K, Mansbach JM, Ajami NJ, Petrosino JF, Freishtat RJ, *et al.* The relationship between nasopharyngeal CCL5 and microbiota on disease severity among infants with bronchiolitis. *Allergy* 2017;72:1796–1800.
92. Luna PN, Hasegawa K, Ajami NJ, Espinola JA, Henke DM, *et al.* The association between anterior nares and nasopharyngeal microbiota in infants hospitalized for bronchiolitis. *Microbiome* 2018;6:2.
93. Hasegawa K, Linnemann RW, Mansbach JM, Ajami NJ, Espinola JA, *et al.* Nasal airway microbiota profile and severe bronchiolitis in infants: A case-control study. *Pediatr Infect Dis J* 2017;36:1044–1051.
94. Stewart CJ, Mansbach JM, Wong MC, Ajami NJ, Petrosino JF, *et al.* Associations of nasopharyngeal metabolome and microbiome with severity among infants with bronchiolitis. A multi-omic analysis. *Am J Respir Crit Care Med* 2017;196:882–891.
95. vandenBergh MR, Biesbroek G, Rossen JW, de Steenhuijsen Piters WA, Bosch AA, *et al.* Associations between pathogens in the upper respiratory tract of young children: interplay between viruses and bacteria. *PLoS One* 2012;7:e47711:10..
96. Man W, van Houten M, Mérelle M, Vlieger A, Chu M, *et al.* Bacterial and viral respiratory tract microbiota and host characteristics in children with lower respiratory tract infections: a matched case-control study. *Lancet Respir Med* 2019;7:417–426.
97. Dubourg G, Edouard S, Raoult D. Relationship between nasopharyngeal microbiota and patient’s susceptibility to viral infection. *Exp Rev Anti-infect Ther* 2019;17:437–447.
98. Ichinohe T, Pang IK, Kumamoto Y, Peaper DR, JH H, *et al.* Microbiota regulates immune defense against respiratory tract influenza A virus infection. *Proc Natl Acad Sci U S A* 2011;108:5354–5359.
99. Thapa S, Runge J, Venkatachalam A, Denne C, Luna R. The nasopharyngeal and gut microbiota in children in a pediatric otolaryngology practice. *Ped Infect Dis J* 2020;39:e226.
100. Manenzhe RI, Moodley C, Abdulgader SM, Robberts FJL, Zar HJ, *et al.* Nasopharyngeal carriage of antimicrobial-resistant pneumococci in an intensively sampled south african birth cohort. *Front Microbiol* 2019;10:610.
101. Moodley D, Reddy L, Mahungu N, Masha R. Factors associated with coverage of cotrimoxazole prophylaxis in HIV-exposed children in South Africa. *PLoS ONE* 2013;8:e63273.
102. Miao Q, Ma Y, Wang Q, Pan J, Zhang Y, *et al.* Microbiological diagnostic performance of metagenomic next-generation

- sequencing when applied to clinical practice. *Clin Infect Dis* 2018;67:S240:S231–S240..
103. Mellmann A, Bletz S, Böking T, Kipp F, Becker K, et al. Real-time genome sequencing of resistant bacteria provides precision infection control in an institutional setting. *J Clin Microbiol* 2016;54:2874–2881.
 104. World Health Organisation. WHO guidelines for the collection of human specimens for laboratory diagnosis of avian influenza infection. 2005. https://www.who.int/influenza/human_animal_interface/virology_laboratories_and_vaccines/guidelines_collection_h5n1_humans/en/
 105. Marty FM, Chen K, Verrill KA. How to Obtain a Nasopharyngeal Swab Specimen. *N Engl J Med* 2020;382:e76.
 106. Hiebert N, Chen B, Sowerby L. Variability in instructions for performance of nasopharyngeal swabs across Canada in the era of COVID-19 – what type of swab is actually being performed? *J Otolaryngol - Head Neck Surg* 2021;50.
 107. Nwaokorie K, Woods R, Crowley J, Walsh M, de Barra E, et al. Analysing the accuracy of healthcare professionals' nasopharyngeal swab technique in SARS-CoV-2 specimen collection. *Academic Meeting of the Irish Otorhinolaryngology / Head and Neck Society* 2020:7.
 108. Flynn M, Kelly M, Dooley J. Nasopharyngeal aspirates vs. nasal swabs for the detection of respiratory pathogens: results of a rapid review protocol. *MedRxiv* 2020.
 109. Hiebert N, Chen B, Sowerby L. Variability in instructions for performance of nasopharyngeal swabs across Canada in the era of COVID-19 – what type of swab is actually being performed? *J Otolaryngol - Head Neck Surg* 2021;50.
 110. Pérez-Losada M, Crandall KA, Freishtat RJ. Two sampling methods yield distinct microbial signatures in the nasopharynxes of asthmatic children. *Microbiome* 2016;4:25.
 111. Yan M, Pamp S, Fukuyama J, Hwang P, Cho D, et al. Nasal micro-environments and interspecific interactions influence nasal microbiota complexity and *S. aureus* carriage. *Cell Host Microbe* 2013;14:631–640.
 112. Wang H, Dai W, Feng X, Zhou Q, Wang H. Microbiota composition in upper respiratory tracts of healthy children in Shenzhen, China, differed with respiratory sites and ages. *BioMed Res Int* 2018;2018:1–8.
 113. Lieberman D, Shleyfer E, Castel H, Terry A, Harman-Boehm I, et al. Nasopharyngeal versus oropharyngeal sampling for isolation of potential respiratory pathogens in adults. *J Clin Microbiol* 2006;44:525–528.
 114. Gritzfeld JF, Roberts P, Roche L, El Batrawy S, Gordon SB. Comparison between nasopharyngeal swab and nasal wash, using culture and PCR, in the detection of potential respiratory pathogens. *BMC Res Notes* 2011;4:122.
 115. Pérez-Losada M, Alamri L, Crandall KA, Freishtat RJ. Nasopharyngeal microbiome diversity changes over time in children with asthma. *PLoS ONE* 2017;12:e0170543.
 116. Kinloch NN, Shahid A, Ritchie G, Dong W, Lawson T, et al. Evaluation of nasopharyngeal swab collection techniques for nucleic acid recovery and participant experience: Recommendations for COVID-19 diagnostics. *Open Forum Infect Dis* 2020;7:ofaa488.
 117. Lu Y, Wang S, Liou M, Shen T, Lu Y-C, et al. Microbiota dysbiosis in fungal rhinosinusitis. *J Clin Med* 2019;8:11.
 118. Carver C, Jones N. Comparative accuracy of oropharyngeal and nasopharyngeal swabs for diagnosis of COVID-19 - CEBM [Internet]. CEBM. 2020. <https://www.cebm.net/covid-19/comparative-accuracy-of-oropharyngeal-and-nasopharyngeal-swabs-for-diagnosis-of-covid-19/>
 119. Leven M, Vercauteren E, Descheemaeker P, van Laer F, Goossens H. Comparison of direct plating and broth enrichment culture for the detection of intestinal colonization by glycopeptide-resistant enterococci among hospitalized patients. *J Clin Microbiol* 1999.
 120. Choo JM, Leong LE, Rogers GB. Sample storage conditions significantly influence faecal microbiome profiles. *Sci Rep* 2015;5:16350.
 121. Shaikh N, Hoberman A, Colborn D, Kearney D, Jeong J. Are nasopharyngeal cultures useful in diagnosis of acute bacterial sinusitis in children. *Clin Ped* 2013;52:1118–1121.
 122. Stępińska M, Olszewska-Sosińska O, Lau-Dworak M, Zieliński-Jurkiewicz B, Trafny E. Identification of Intracellular Bacteria in Adenoid and Tonsil Tissue Specimens: The Efficiency of Culture Versus Fluorescent In Situ Hybridization (FISH). *Curr Microbiol* 2013;68:21–29.
 123. Tokman H, Aslan M, Kalayci F, Demir T, Kocazeybek B. Microorganisms in respiratory tract of patients diagnosed with atypical pneumonia: Results of a research based on the use of reverse transcription polymerase chain reaction (RT-PCR) DNA. *Clin Lab* 2014;60:06.
 124. Arevalo-Rodriguez I, Buitrago-Garcia D, Simancas-Racines D, Zambrano-Achig P, del Campo R, et al. False-negative results of initial RT-PCR assays for COVID-19: A systematic Review. *medRxiv Pre-print* 2020.
 125. Rutebemberwa E, Mpeka B, Pariyo G, Peterson S, Mworozzi E, et al. High prevalence of antibiotic resistance in nasopharyngeal bacterial isolates from healthy children in rural Uganda: A cross-sectional study. *Ups J Med Sci* 2015;120:249–256.
 126. Mika M, Maurer J, Kortgen I, Allemann A, Aebi S, et al. Influence of the pneumococcal conjugate vaccines on the temporal variation of pneumococcal carriage and the nasal microbiota in healthy infants: a longitudinal analysis of a case-control study. *Microbiome* 2017;5.
 127. Glück U, Gebbers J. Ingested probiotics reduce nasal colonization with pathogenic bacteria (*Staphylococcus aureus*, *Streptococcus pneumoniae*, and β -hemolytic streptococci). *Am J Clin Nut* 2003;77:517–520.
 128. Uehara Y, Nakama H, Agematsu K, Uchida M, Kawakami Y, et al. Bacterial interference among nasal inhabitants: eradication of *Staphylococcus aureus* from nasal cavities by artificial implantation of *Corynebacterium* sp. *J Hosp Infect* 2000;44:127–133.
 129. Kanmani P, Clua P, Vizoso-Pinto MG, Rodriguez C, Alvarez S, et al. Respiratory commensal bacteria *Corynebacterium pseudodiphtheriticum* improves resistance of infant mice to respiratory syncytial virus and *Streptococcus pneumoniae* superinfection. *Front Microbiol* 2017;8:1613.
 130. Quainoo S, Coolen JPM, van Hijum SAFT, Huynen MA, Melchers WJG, et al. Whole-genome sequencing of bacterial pathogens: the future of nosocomial outbreak analysis. *Clin Microbiol Rev* 2017;30:1015–1063.
 131. Meredith L, Hamilton W, Warne B, Houldcroft C, Hosmillo M, et al. Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study. *Lancet Infect Dis* 2020;20:1263–1271.
 132. Couturier M, Bard J. Direct-from-specimen pathogen identification. *Clin Lab Med* 2019;39:433–451.
 133. van Belkum A, Rochas O. Laboratory-based and point-of-care testing for MSSA/MRSA detection in the age of whole genome sequencing. *Front Microbiol* 2018;9:1437.
 134. Abramson M, Wolfe R. Prediction models in respiratory medicine. *Respirology* 2020;25:666–667.
 135. Lamarche D, Johnstone J, Zytaruk N, Clarke F, Hand L, et al. Microbial dysbiosis and mortality during mechanical ventilation: a prospective observational study. *Respir Res* 2018;19.
 136. Xu Z, Xie Z, Sun J, Huang S, Chen Y, et al. Gut microbiome reveals specific dysbiosis in primary osteoporosis. *Front Cell Infect Microbiol* 2020;10:160.
 137. Kwak S, Choi J, Hink T, Reske K, Blount K, et al. Impact of investigational microbiota therapeutic RBX2660 on the gut microbiome and resistome revealed by a placebo-controlled clinical trial. *Microbiome* 2020;8.